Prokidney Corp. (PROK)
NASDAQ:PROK
Want to see PROK full AI Analyst Report?
PROK Stock Chart & Stats
$1.66
-$0.14(-7.65%)
At close: 4:00 PM EST
$1.66
-$0.14(-7.65%)
Day’s Range― - ―
52-Week Range$0.54 - $7.13
Previous CloseN/A
Volume58.77K
Average Volume (3M)921.71K
Market Cap
$504.44M
Enterprise Value$470.16M
Total Cash (Recent Filing)$224.94M
Total Debt (Recent Filing)$3.78M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding205,199,700
10 Day Avg. Volume1,032,039
30 Day Avg. Volume921,708
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue528.86
Enterprise Value/Gross Profit-235.67
Enterprise Value/Ebitda-3.13
Forecast
1Y Price Target
$5.75Price Target Upside246.39% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$511.14K
Bulls Say, Bears Say
Bulls Say
Regulatory Alignment & Phase 3 ProgressFDA alignment on using eGFR slope as a surrogate and a Phase 3 enrollment program that remains on track materially reduces regulatory uncertainty versus an unaligned program. This durable structural improvement raises the probability the pivotal trial can support an accelerated approval pathway if data are positive.
Cash Runway Into Mid‑2027A reported cash and securities balance funding operations into mid-2027 provides sufficient runway to reach the pivotal topline readout in 2Q 2027. That runway reduces immediate financing pressure and allows focus on completing the pivotal trial, a durable operational benefit while the program advances.
Low Leverage (minimal Debt)Extremely low absolute debt and a near-zero debt-to-equity ratio lower short-term financial distress risk and reduce fixed financing costs. This structural balance-sheet strength gives the company flexibility to pursue equity financings, partnerships, or milestone-based collaborations without high leverage constraints.
Bears Say
High Cash BurnSustained, large negative operating and free cash flows indicate the company is a significant cash consumer. Over the medium term this necessitates additional financing or partnerships, which can dilute existing shareholders or divert management focus, and is a persistent constraint until commercialization or sustained non-dilutive revenues occur.
Minimal And Declining RevenueWith negligible and falling revenue, ProKidney lacks product-derived cash generation and relies on financing, collaborations or asset sales to fund R&D. This structural absence of recurring revenue increases dependence on capital markets and heightens execution risk until an approved therapy produces sustainable sales.
Pre‑commercial Single‑asset Risk And Heavy LossesLarge recurring operating losses coupled with a primarily single therapeutic asset create a binary long-term outcome: success drives commercialization; failure materially impairs value. The structural concentration of R&D spend on one program and sustained losses prolong runway dependence and elevate enterprise risk.
ProKidney News
PROK FAQ
What was Prokidney Corp.’s price range in the past 12 months?
Prokidney Corp. lowest stock price was $0.54 and its highest was $7.13 in the past 12 months.
What is Prokidney Corp.’s market cap?
Prokidney Corp.’s market cap is $504.44M.
When is Prokidney Corp.’s upcoming earnings report date?
Prokidney Corp.’s upcoming earnings report date is Aug 06, 2026 which is in 50 days.
How were Prokidney Corp.’s earnings last quarter?
Prokidney Corp. released its earnings results on May 15, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.138 by -$0.002.
Is Prokidney Corp. overvalued?
According to Wall Street analysts Prokidney Corp.’s price is currently Undervalued.
Does Prokidney Corp. pay dividends?
Prokidney Corp. does not currently pay dividends.
What is Prokidney Corp.’s EPS estimate?
Prokidney Corp.’s EPS estimate is -0.14.
How many shares outstanding does Prokidney Corp. have?
Prokidney Corp. has 205,199,700 shares outstanding.
What happened to Prokidney Corp.’s price movement after its last earnings report?
Prokidney Corp. reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.138. Following the earnings report the stock price went down -2.924%.
Which hedge fund is a major shareholder of Prokidney Corp.?
Currently, no hedge funds are holding shares in PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.75 (246.39% Upside)
$5.75 (246.39% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 54.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
99.28%
12-Months-Change
Fundamentals
Return on Equity
7.40%
Trailing 12-Months
Asset Growth
-27.90%
Trailing 12-Months
Company Description
Prokidney Corp.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$5.75
▲(246.39% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
49.16% Insiders
1.94% Mutual Funds
8.71% Other Institutional Investors
39.28% Public Companies and
Individual Investors